Skip to main content
Caplight Logo









SpeeDx

SpeeDx

Private
SydneyHealthcare & Life Scienceshttps://www.speedxpcr.com/

Last Round

Series C

Feb 28, 2023

Total Funding Raised

$52.01M

Company Overview

SpeeDx is a molecular diagnostics company that develops innovative multiplex systems for clinical diagnostics utilizing real-time polymerase chain reaction technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

molecular diagnosticsqPCRmultiplex PCRinfectious disease testingantibiotic resistance testingdiagnostic assaysprecision medicineSTI testingrespiratory viral panelsmolecular testingpathology diagnosticsdiagnostic kitslab diagnosticsclinical diagnosticsbiotech reagents

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SpeeDx Comparables

Compare SpeeDx with similar companies based on industry and business-model similarity.

SpeeDx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ChromaCode
80%
Seegene Inc.
79%
R-Biopharm AG
78%

SpeeDx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 28, 2023
GrantJul 16, 2021
GrantMay 10, 2021
GrantSep 3, 2020
Series BFeb 11, 2020
Series A
Aug 5, 2019

Key People

Founding team and executive leadership

Alison V. Todd AM FTSE

Chief Scientific Officer Founder

Founding Team

Jeremy Stackawitz

Chief Executive Officer

Executive Team

Elisa M.

Chief Technology Officer

Executive Team

SpeeDx Investors

Notable investors and investment history

SpeeDx investors
InvestorRounds
CARB-XGrant
Platinum Asset ManagementSeries C
NSW Medical Device FundGrant
Northpond VenturesSeries C, Series A, Series B
TattarangSeries C
Northpond VenturesSeries C, Series A, Series B
Australian Government Department of Industry, Science and ResourcesGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 28, 2023

    $17M round led by Platinum Asset Management and Tattarang.

  • May 10, 2021

    $1.8M grant awarded by CARB-X

SpeeDx Filings

Explore SEC and related filing metadata, where available.

SpeeDx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SpeeDx's valuation, stock price, and market status.

Is SpeeDx a public or private company?

SpeeDx is a private company.

What is the current stock price of SpeeDx?

SpeeDx is a private company with no public stock price. No recent secondary market data is available.

How much is SpeeDx worth (valuation)?

Valuation information for SpeeDx is not publicly available.

Can I buy SpeeDx stock?

SpeeDx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SpeeDx's last funding round?

SpeeDx's most recent funding round was Series C on February 28, 2023.

Who are the main investors in SpeeDx?

Key investors in SpeeDx include Platinum Asset Management, Tattarang, Northpond Ventures, Tenmile.

Will SpeeDx IPO soon?

No public IPO plans have been announced for SpeeDx.

How can I track SpeeDx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SpeeDx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSydney
Employee Range61
Year Founded2009
Last FundingFeb 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?